These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38569441)

  • 1. Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis.
    Fukuda Y; Uchida Y; Ando K; Manabe R; Tanaka A; Sagara H
    Respir Investig; 2024 May; 62(3):481-487. PubMed ID: 38569441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
    Kashizaki F; Chen H; Miyasaka A; Tsuchiya N; Yamada C; Okazaki S; Kaneko M; Kano T; Kameda Y; Kikuchi A; Yumoto K; Osawa H; Koizumi H; Takahashi K; Kaneko T
    Clin Lung Cancer; 2024 Jan; 25(1):e52-e57.e2. PubMed ID: 37932180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
    Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
    Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
    Qi WX; Sun YJ; Shen Z; Yao Y
    J Chemother; 2015 Feb; 27(1):40-51. PubMed ID: 24724908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database.
    Okada N; Hamano H; Yagi K; Niimura T; Aizawa F; Goda M; Zamami Y; Kitahara T; Ishizawa K
    Int J Clin Pharmacol Ther; 2024 Feb; 62(2):69-76. PubMed ID: 37969096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
    Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
    Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
    Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
    Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
    Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
    Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
    Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
    Ohmori T; Yamaoka T; Ando K; Kusumoto S; Kishino Y; Manabe R; Sagara H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
    Zhao M; Liu S; Xie R; Zhang J; Li J
    Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.
    Nasu S; Suzuki H; Shiroyama T; Tanaka A; Samejima Y; Kanai T; Noda Y; Morishita N; Okamoto N; Hirashima T
    Invest New Drugs; 2020 Dec; 38(6):1915-1920. PubMed ID: 32542461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.
    Yoneda KY; Hardin KA; Gandara DR; Shelton DK
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S31-5. PubMed ID: 17239288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
    Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
    J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.